Ask Warren

BioPlus

099430 · KOSDAQ · ₩099430 · 바이오플러스

₩3,200▼ ₩210 (6.16%)End-of-day · Oct 30, 2026 · End-of-day prices.
Trade
Alert me
SellBuy
AnnualQuarterly

Income statement

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Revenue₩25B₩27B₩23B₩24B₩21B₩23B₩29B₩16B
Cost of sales₩8B₩8.3B₩8.3B₩6.5B₩7.6B₩7.8B₩7.9B₩6.7B
Gross profit₩17B₩18B₩15B₩18B₩13B₩15B₩21B₩9.7B
Operating income₩6.2B₩5.7B₩963M₩4.9B₩2.1B₩7.1B₩14B₩4.7B
Net income−₩4.3B₩8B₩3.6B₩4.4B₩3.4B₩8.5B₩4.5B₩4.1B
Net income to shareholders₩2B₩6.7B₩2B₩3.1B₩2.2B₩7.7B₩3.1B₩3.3B

Balance sheet

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Total assets₩297B₩297B₩285B₩293B₩271B₩278B₩264B₩248B
Current assets₩68B₩71B₩65B₩86B₩52B₩85B₩77B₩96B
Cash and equivalents₩20B₩23B₩21B₩26B₩12B₩26B₩39B₩63B
Total liabilities₩96B₩98B₩90B₩104B₩100B₩112B₩117B₩106B
Current liabilities₩72B₩76B₩77B₩94B₩96B₩108B₩112B₩102B
Borrowings₩61B₩61B₩56B₩58B₩5.4B₩54B₩53B₩52B
Total equity₩200B₩199B₩195B₩189B₩171B₩166B₩148B₩142B
Shareholders' equity₩178B₩178B₩175B₩171B₩154B₩150B₩133B₩129B

Cash flow

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Cash from operations₩1.4B₩5.3B₩4B₩3.6B₩1.4B₩5.7B₩4.8B₩6.8B
Capital spending₩1.9B₩2.7B₩8.9B₩5.4B₩14B₩19B₩26B₩24B
Free cash flow−₩490M₩2.6B−₩4.9B−₩1.8B−₩12B−₩13B−₩21B−₩17B
Dividends paid−₩18M₩4.3B—————₩0

Consolidated where available. Amounts in won.

Also known as: BioPlus / 바이오플러스 / 099430 / KRX:099430

Source: KRX statistical information